Abstract
Background: Atidarsagene autotemcel (arsa-cel) is an ex vivo, lentiviral, autologous, hematopoietic stem cell–based gene therapy approved for the treatment of children with early-onset metachromatic leukodystrophy (MLD). This case series describes early experience with arsa-cel treatment in the United States and provides information on variable paths to identification and diagnosis of patients with MLD. Methods: Prior to approval by the US Food and Drug Administration, five patients classified as having early-onset MLD were treated with arsa-cel on a single-patient compassionate use basis at the University of Minnesota. Results: Two patients with presymptomatic late-infantile MLD were identified because of older siblings with MLD. Three patients were identified because of gallbladder disease, cranial neuropathy, or motor delays. All patients achieved hematologic recovery, and leukocyte arylsulfatase A activity increased to normal or above-normal levels within 30 days posttreatment. After 24 to 48 months (median, 36 months) of follow-up, the three patients who were presymptomatic at the time of treatment were independently ambulatory at last assessment. The two patients with early symptomatic early-juvenile MLD experienced cognitive and neurologic deterioration. Conclusion: This case series provides examples of the variety of clinical presentations in patients with MLD and emphasizes the importance of prompt diagnosis and referral of patients with early-onset MLD to provide the best opportunity to achieve optimal outcomes.